Compare Lucid Group Inc (LCID) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Merck & Co., Inc. — how do they compare? Lucid Group Inc trades at $7.11 (market cap $2.77B), while Merck & Co., Inc. trades at $124.78 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 110.9× Lucid Group Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | MRK | |
|---|---|---|
Market Cap | $2.77B | $307.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.30 | $129.52 |
52-Week Low | $4.62 | $77.60 |
Enterprise Value | $5.24B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $7.33, down 0.41% on the day, amid mixed technical signals and severe fundamental challenges. The stock shows a bullish moving average trend but bearish oscillators, with RSI at 70.77 suggesting overbought conditions. Financially, the company reported a net loss of $2.70 billion on $1.35 billion revenue in 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Recent news highlights class-action lawsuits and bankruptcy rumors, though management denies financial distress.
The outlook remains highly speculative with significant execution and liquidity risks. Analyst consensus is cautious, with 66.7% hold ratings and a $10.50 price target implying limited upside. Investment appeal hinges on Lucid's ability to achieve profitability and scale production, but current financials and legal overhangs present substantial headwinds for near-term performance.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
